James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.
Researchers have developed a brain-permeable compound (25-106) that targets a signaling regulator in brain neurons. The team notes that when the new compound was administered to mice, it could alter their neurobehavior and reduce anxiety-like behavior.
Novel preclinical drug could have potential to combat depression, brain injury and cognitive disorders miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.